menu
    • menu
    [{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Private Placement","leadProduct":"Gentamicin Sulfate","moa":"||30S ribosomal subunit","graph1":"Dermatology","graph2":"Phase I","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Lotion","sponsorNew":"Hoth Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"6","companyTruncated":"Hoth Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Private Placement","leadProduct":"Gentamicin Sulfate","moa":"||30S ribosomal subunit","graph1":"Dermatology","graph2":"Phase I","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Lotion","sponsorNew":"Hoth Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"6","companyTruncated":"Hoth Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Private Placement","leadProduct":"Gentamicin Sulfate","moa":"||30S ribosomal subunit","graph1":"Dermatology","graph2":"Phase I","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Lotion","sponsorNew":"Hoth Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"6","companyTruncated":"Hoth Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Gentamicin Sulfate","moa":"30S ribosomal subunit","graph1":"Dermatology","graph2":"Phase I","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Lotion","sponsorNew":"Hoth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Hoth Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Gentamicin Sulfate","moa":"30S ribosomal subunit","graph1":"Dermatology","graph2":"Phase I","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Lotion","sponsorNew":"Hoth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Hoth Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Novotech","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Gentamicin Sulfate","moa":"||30S ribosomal subunit","graph1":"Dermatology","graph2":"Phase I","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Lotion","sponsorNew":"Hoth Therapeutics \/ Novotech","highestDevelopmentStatusID":"6","companyTruncated":"Hoth Therapeutics \/ Novotech"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Novotech","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Gentamicin Sulfate","moa":"||30S ribosomal subunit","graph1":"Dermatology","graph2":"Phase I","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Lotion","sponsorNew":"Hoth Therapeutics \/ Novotech","highestDevelopmentStatusID":"6","companyTruncated":"Hoth Therapeutics \/ Novotech"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Novotech","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Gentamicin Sulfate","moa":"||30S ribosomal subunit","graph1":"Dermatology","graph2":"Phase I","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Lotion","sponsorNew":"Hoth Therapeutics \/ Novotech","highestDevelopmentStatusID":"6","companyTruncated":"Hoth Therapeutics \/ Novotech"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Novotech","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Gentamicin Sulfate","moa":"||30S ribosomal subunit","graph1":"Dermatology","graph2":"Phase I","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Lotion","sponsorNew":"Hoth Therapeutics \/ Novotech","highestDevelopmentStatusID":"6","companyTruncated":"Hoth Therapeutics \/ Novotech"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Novotech","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Gentamicin Sulfate","moa":"||30S ribosomal subunit","graph1":"Dermatology","graph2":"Phase I","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Lotion","sponsorNew":"Hoth Therapeutics \/ Novotech","highestDevelopmentStatusID":"6","companyTruncated":"Hoth Therapeutics \/ Novotech"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Gentamicin Sulfate","moa":"||30S ribosomal subunit","graph1":"Dermatology","graph2":"Phase I","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Lotion","sponsorNew":"Hoth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Hoth Therapeutics \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Gentamicin Sulfate

    Menu

    Gentamicin Sulfate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
    filter

    Year

    filter

    DEALS // DEV.

    filter

    Country

    filter
    Sponsor
    filter

    Therapeutic Area

    filter

    Study Phase

    filter

    Deal Type

    filter

    Product Type

    filter

    Dosage Form

    filter

    Lead Product

    filter

    Target

    refresh Filters
    refresh Reset Filter
    refresh Reset Filter
    price-trend All Developments

    Therapeutic Area by Lead Product

    ForexGraph

    Study Phase by Lead Product

    ForexGraph

    Company by Lead Product

    ForexGraph

    Top Deals by Deal Size (USD bn)

    ForexGraph

    01

    Hoth Therapeutics

    U.S.A arrow
    MAGHREB PHARMA
    Not Confirmed

    Hoth Therapeutics

    U.S.A arrow
    MAGHREB PHARMA
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Gentamicin Sulfate

    Therapeutic Area : Dermatology

    Study Phase : Phase I

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Hoth Therapeutics Announces Positive Final Results from 14-day Phase 1b Clinical Trial of BioLexa

    Details : BioLexa (gentamicin) is a patented, proprietary antimicrobial topical formulation being developed for treatment of atopic dermatitis. Bacterial biofilms are specialized communities consisting of bacteria adhered to a surface and to other bacteria.

    Product Name : BioLexa

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    June 09, 2023

    Lead Product(s) : Gentamicin Sulfate

    Therapeutic Area : Dermatology

    Highest Development Status : Phase I

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    02

    Hoth Therapeutics

    U.S.A arrow
    Cophex
    Not Confirmed

    Hoth Therapeutics

    U.S.A arrow
    Cophex
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Gentamicin Sulfate,Pentetic Acid

    Therapeutic Area : Dermatology

    Study Phase : Phase I

    Sponsor : H.C. Wainwright & Co

    Deal Size : $10.0 million

    Deal Type : Private Placement

    DEALS_DEV arrow-down

    Hoth Therapeutics Announces Closing of $10 Million Private Placement Priced At-the-Market Under Nasdaq Rules

    Details : BioLexa (gentamicin) is a patented, proprietary antimicrobial topical formulation being developed for treatment of diseases mediated by Staphylococcal biofilms. Bacterial biofilms are specialized communities consisting of bacteria adhered to a surface an...

    Product Name : BioLexa

    Product Type : Other Small Molecule

    Upfront Cash : Undisclosed

    March 01, 2023

    Lead Product(s) : Gentamicin Sulfate,Pentetic Acid

    Therapeutic Area : Dermatology

    Highest Development Status : Phase I

    Sponsor : H.C. Wainwright & Co

    Deal Size : $10.0 million

    Deal Type : Private Placement

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    03

    Hoth Therapeutics

    U.S.A arrow
    MAGHREB PHARMA
    Not Confirmed

    Hoth Therapeutics

    U.S.A arrow
    MAGHREB PHARMA
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Gentamicin Sulfate,Pentetic Acid

    Therapeutic Area : Dermatology

    Study Phase : Phase I

    Sponsor : H.C. Wainwright & Co

    Deal Size : $10.0 million

    Deal Type : Private Placement

    DEALS_DEV arrow-down

    Hoth Therapeutics Announces $10 Million Private Placement Priced At-the-Market Under Nasdaq Rules

    Details : BioLexa (gentamicin) is a patented, proprietary antimicrobial topical formulation being developed for treatment of diseases mediated by Staphylococcal biofilms. The BioLexa formulation is optimized to prevent Staphylococcal biofilm formation.

    Product Name : BioLexa

    Product Type : Other Small Molecule

    Upfront Cash : Undisclosed

    December 29, 2022

    Lead Product(s) : Gentamicin Sulfate,Pentetic Acid

    Therapeutic Area : Dermatology

    Highest Development Status : Phase I

    Sponsor : H.C. Wainwright & Co

    Deal Size : $10.0 million

    Deal Type : Private Placement

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    04

    Hoth Therapeutics

    U.S.A arrow
    MAGHREB PHARMA
    Not Confirmed

    Hoth Therapeutics

    U.S.A arrow
    MAGHREB PHARMA
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Gentamicin Sulfate

    Therapeutic Area : Dermatology

    Study Phase : Phase I

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Hoth Therapeutics Announces HREC Approval in Australia for the Next Phase of its Trial of BioLexa for Patients...

    Details : BioLexa is a patented, proprietary antimicrobial topical formulation being developed for treatment of diseases mediated by Staphylococcal biofilms for patients suffering with Atopic Dermatitis.

    Product Name : BioLexa

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    June 21, 2022

    Lead Product(s) : Gentamicin Sulfate

    Therapeutic Area : Dermatology

    Highest Development Status : Phase I

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    05

    Hoth Therapeutics

    U.S.A arrow
    MAGHREB PHARMA
    Not Confirmed

    Hoth Therapeutics

    U.S.A arrow
    MAGHREB PHARMA
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Gentamicin Sulfate,Pentetic Acid

    Therapeutic Area : Dermatology

    Study Phase : Phase I

    Sponsor : Novotech

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Hoth Therapeutics Receives Approval to Commence Cohort 2 in Clinical Trial of BioLexa for the Treatment of Ato...

    Details : Receiving clearance for Cohort 2 is the next critical milestone in the Phase 1b clinical trial in Australia. Hoth's atopic dermatitis solution, BioLexa, represents a significant global opportunity and looks forward to advancing the treatment through the ...

    Product Name : BioLexa

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    December 10, 2021

    Lead Product(s) : Gentamicin Sulfate,Pentetic Acid

    Therapeutic Area : Dermatology

    Highest Development Status : Phase I

    Sponsor : Novotech

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    06

    Hoth Therapeutics

    U.S.A arrow
    MAGHREB PHARMA
    Not Confirmed

    Hoth Therapeutics

    U.S.A arrow
    MAGHREB PHARMA
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Gentamicin Sulfate,Pentetic Acid

    Therapeutic Area : Dermatology

    Study Phase : Phase I

    Sponsor : Novotech

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Hoth Therapeutics Submits to Ethics Committee for Approval to Initiate Patient Cohort 2 in BioLexa Clinical Tr...

    Details : BioLexa is patented, proprietary antimicrobial topical formulation against diseases mediated by Staphylococcal biofilms. BioLexa formulation is optimized to prevent Staphylococcal biofilm formation, keeping bacteria in more susceptible state to antimicro...

    Product Name : BioLexa

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    September 21, 2021

    Lead Product(s) : Gentamicin Sulfate,Pentetic Acid

    Therapeutic Area : Dermatology

    Highest Development Status : Phase I

    Sponsor : Novotech

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    07

    Hoth Therapeutics

    U.S.A arrow
    MAGHREB PHARMA
    Not Confirmed

    Hoth Therapeutics

    U.S.A arrow
    MAGHREB PHARMA
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Gentamicin Sulfate,Pentetic Acid

    Therapeutic Area : Dermatology

    Study Phase : Phase I

    Sponsor : H.C. Wainwright & Co

    Deal Size : $15.0 million

    Deal Type : Private Placement

    DEALS_DEV arrow-down

    Hoth Therapeutics Announces $15 Million Private Placement Priced At-the-Market Under Nasdaq Rules

    Details : The Company currently intends to use the net proceeds from the private placement for further development of Hoth's product candidates including lead drug BioLexa and for working capital and general corporate purposes.

    Product Name : BioLexa

    Product Type : Other Small Molecule

    Upfront Cash : Undisclosed

    August 03, 2021

    Lead Product(s) : Gentamicin Sulfate,Pentetic Acid

    Therapeutic Area : Dermatology

    Highest Development Status : Phase I

    Sponsor : H.C. Wainwright & Co

    Deal Size : $15.0 million

    Deal Type : Private Placement

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    08

    Hoth Therapeutics

    U.S.A arrow
    MAGHREB PHARMA
    Not Confirmed

    Hoth Therapeutics

    U.S.A arrow
    MAGHREB PHARMA
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Gentamicin Sulfate,Pentetic Acid

    Therapeutic Area : Dermatology

    Study Phase : Phase I

    Sponsor : Novotech

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Hoth Therapeutics' First in Human Clinical Trial for the Treatment of Atopic Dermatitis with BioLexa is Underw...

    Details : The first in human clinical trial is randomized, double-blind, vehicle controlled study to determine the safety, tolerability, PK and efficacy of twice daily application of topical BioLexa™ lotion, in adult and adolescent patients with mild to moderate...

    Product Name : BioLexa

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    April 22, 2021

    Lead Product(s) : Gentamicin Sulfate,Pentetic Acid

    Therapeutic Area : Dermatology

    Highest Development Status : Phase I

    Sponsor : Novotech

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    09

    Hoth Therapeutics

    U.S.A arrow
    MAGHREB PHARMA
    Not Confirmed

    Hoth Therapeutics

    U.S.A arrow
    MAGHREB PHARMA
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Gentamicin Sulfate,Pentetic Acid

    Therapeutic Area : Dermatology

    Study Phase : Phase I

    Sponsor : Novotech

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Hoth Therapeutics Completes Site Recruitment for Cohort 1 of First in Human Clinical Trial of BioLexa for the ...

    Details : Hoth Therapeutics has completed recruitment of Cohort 1 for its upcoming first in human clinical trial of the proprietary BioLexa platform to treat atopic dermatitis, also known as eczema.

    Product Name : BioLexa

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    January 03, 2021

    Lead Product(s) : Gentamicin Sulfate,Pentetic Acid

    Therapeutic Area : Dermatology

    Highest Development Status : Phase I

    Sponsor : Novotech

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    10

    Hoth Therapeutics

    U.S.A arrow
    MAGHREB PHARMA
    Not Confirmed

    Hoth Therapeutics

    U.S.A arrow
    MAGHREB PHARMA
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Gentamicin Sulfate,Pentetic Acid

    Therapeutic Area : Dermatology

    Study Phase : Phase I

    Sponsor : Novotech

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Hoth Therapeutics Receives Approval to Commence Phase 1b Clinical Trial of BioLexa for the Treatment of Atopic...

    Details : Following the successful completion of the Phase 1b trial, the Company intends to conduct a Phase 2 trial with adult and adolescent patients to continue clinical investigation of the efficacy of BioLexa Lotion for treatment of mild to moderate atopic der...

    Product Name : BioLexa

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    October 12, 2020

    Lead Product(s) : Gentamicin Sulfate,Pentetic Acid

    Therapeutic Area : Dermatology

    Highest Development Status : Phase I

    Sponsor : Novotech

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth